244 related articles for article (PubMed ID: 15614015)
21. Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging.
Scalera F; Martens-Lobenhoffer J; Bukowska A; Lendeckel U; Täger M; Bode-Böger SM
Hypertension; 2008 Mar; 51(3):696-703. PubMed ID: 18250362
[TBL] [Abstract][Full Text] [Related]
22. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
23. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
Ikejima H; Imanishi T; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
J Hypertens; 2008 May; 26(5):964-72. PubMed ID: 18398339
[TBL] [Abstract][Full Text] [Related]
24. Antihypertensive agents acting on the renin-angiotensin system and the risk of sepsis.
Dial S; Nessim SJ; Kezouh A; Benisty J; Suissa S
Br J Clin Pharmacol; 2014 Nov; 78(5):1151-8. PubMed ID: 24803383
[TBL] [Abstract][Full Text] [Related]
25. Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.
Michel MC; Brunner HR; Foster C; Huo Y
Pharmacol Ther; 2016 Aug; 164():1-81. PubMed ID: 27130806
[TBL] [Abstract][Full Text] [Related]
26. Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers.
Kintscher U; Unger T
Acta Diabetol; 2005 Apr; 42 Suppl 1():S26-32. PubMed ID: 15868116
[TBL] [Abstract][Full Text] [Related]
27. Effects of telmisartan on metabolic syndrome components: a comprehensive review.
Imenshahidi M; Roohbakhsh A; Hosseinzadeh H
Biomed Pharmacother; 2024 Feb; 171():116169. PubMed ID: 38228033
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?
Benson SC; Iguchi R; Ho CI; Yamamoto K; Kurtz TW
J Hypertens; 2008 May; 26(5):973-80. PubMed ID: 18398340
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.
Schupp M; Janke J; Clasen R; Unger T; Kintscher U
Circulation; 2004 May; 109(17):2054-7. PubMed ID: 15117841
[TBL] [Abstract][Full Text] [Related]
30. Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice.
Blessing E; Preusch M; Kranzhöfer R; Kinscherf R; Marx N; Rosenfeld ME; Isermann B; Weber CM; Kreuzer J; Gräfe J; Katus HA; Bea F
Atherosclerosis; 2008 Aug; 199(2):295-303. PubMed ID: 18093593
[TBL] [Abstract][Full Text] [Related]
31. HIV protease inhibitors activate the adipocyte renin angiotensin system.
Boccara F; Auclair M; Cohen A; Lefèvre C; Prot M; Bastard JP; Capeau J; Caron-Debarle M
Antivir Ther; 2010; 15(3):363-75. PubMed ID: 20516556
[TBL] [Abstract][Full Text] [Related]
32. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes.
Jandeleit-Dahm KA; Tikellis C; Reid CM; Johnston CI; Cooper ME
J Hypertens; 2005 Mar; 23(3):463-73. PubMed ID: 15716683
[TBL] [Abstract][Full Text] [Related]
33. Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes.
Pang T; Benicky J; Wang J; Orecna M; Sanchez-Lemus E; Saavedra JM
J Hypertens; 2012 Jan; 30(1):87-96. PubMed ID: 22124178
[TBL] [Abstract][Full Text] [Related]
34. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.
Benson SC; Pershadsingh HA; Ho CI; Chittiboyina A; Desai P; Pravenec M; Qi N; Wang J; Avery MA; Kurtz TW
Hypertension; 2004 May; 43(5):993-1002. PubMed ID: 15007034
[TBL] [Abstract][Full Text] [Related]
35. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
[TBL] [Abstract][Full Text] [Related]
36. Telmisartan is the most effective ARB to increase adiponectin via PPARα in adipocytes.
Hattori N; Yamada A; Nakatsuji S; Matsuda T; Nishiyama N; Shimatsu A
J Mol Endocrinol; 2022 May; 69(1):259-268. PubMed ID: 35354667
[TBL] [Abstract][Full Text] [Related]
37. Adiponectin elevation by telmisartan ameliorates ischaemic myocardium in Zucker diabetic fatty rats with metabolic syndrome.
Rinaldi B; Di Filippo C; Capuano A; Donniacuo M; Sodano L; Ferraraccio F; Rossi F; D'Amico M
Diabetes Obes Metab; 2012 Apr; 14(4):320-8. PubMed ID: 22050607
[TBL] [Abstract][Full Text] [Related]
38. Telmisartan - killing two birds with one stone.
Doggrell SA
Expert Opin Pharmacother; 2004 Nov; 5(11):2397-400. PubMed ID: 15500387
[TBL] [Abstract][Full Text] [Related]
39. Telmisartan: just an antihypertensive agent? A literature review.
Destro M; Cagnoni F; Dognini GP; Galimberti V; Taietti C; Cavalleri C; Galli E
Expert Opin Pharmacother; 2011 Dec; 12(17):2719-35. PubMed ID: 22077832
[TBL] [Abstract][Full Text] [Related]
40. Are the pleiotropic effects of telmisartan clinically relevant?
Rizos CV; Elisaf MS; Liberopoulos EN
Curr Pharm Des; 2009; 15(24):2815-32. PubMed ID: 19689352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]